Senti Biosciences Q2 2026 Earnings Report

Senti Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.33
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Senti Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.02 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Senti Biosciences Announcement Details

• Quarter: Q2 2026
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Senti Biosciences (NASDAQ:SNTI) (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities.

Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.